Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates

分组1 - Verastem reported a quarterly loss of $0.5 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.49, but an improvement from a loss of $1.33 per share a year ago, indicating an earnings surprise of -2.04% [1] - The company generated revenues of $17.54 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.20%, compared to zero revenues in the same quarter last year [2] - Verastem shares have declined approximately 26.4% since the beginning of the year, contrasting with the S&P 500's decline of 0.4% [3] 分组2 - The earnings outlook for Verastem is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.46 on revenues of $22.8 million, and for the current fiscal year at -$1.86 on revenues of $134.45 million [7] - The Zacks Industry Rank places the Medical - Biomedical and Genetics sector in the bottom 44% of over 250 Zacks industries, suggesting that the industry outlook could significantly impact stock performance [8] - Foghorn Therapeutics Inc., another company in the same industry, is expected to report a quarterly loss of $0.28 per share, with revenues projected to be $8.05 million, reflecting a year-over-year increase of 181.5% [9]